AXXAM TO INTEGRATE IPA 3.0 INTO ITS GENE EXPRESSION PLATFORM
Milan, Italy and Redwood City, CA – Nov 9, 2005 – Axxam and Ingenuity today announced that they have entered into an agreement for the licensing of IPA 3.0, significantly accelerating Axxam in their genes-to-targets discovery process. Axxam will integrate the newest release of the IPA into its gene expression platform.
Axxam conducts global expression analysis on common diseases to identify the major players involved in these diseases and their interactions, which provide the basis for comprehensive pathology understanding and therapeutic target identification. Axxam is also involved in gene-by-gene quantitative HT expression profiling through its proprietary database (GeneTrawler®), with a main focus on druggable gene products. The IPA application is being applied to Axxam research programs in several selected therapeutic areas to identify novel targets.
IPA 3.0 enables researchers to model, analyze and understand the complex biological systems at the core of life science research. With IPA, scientists can integrate their own biological discoveries into Ingenuity networks, enabling more powerful computation and functional analysis. The Ingenuity application allows scientists to create customized pathways for particular targets, biomarkers, disease areas, and processes, leveraging Ingenuity’s broad knowledge base of biological relationships between genes and proteins, cells, tissues, and diseases.
Fully functional complimentary trials of the NEW IPA 3.0 are available to qualified scientists at http://www.ingenuity.com/trial/start.html.
Axxam is a research-driven biotechnology company with leading expertise, know-how and cutting-edge technologies for the early stages of the drug discovery process, “from genes to leads.” Axxam’s main activities are related to target analysis and selection by comprehensive genome analysis and accurate expression profiling, comprehensive and state-of-the-art technology platforms for the development of screening assays, functional luminescence and fluorescence cell-based and biochemical assays in 384 and 1536 MTPs, and hit and lead discovery programs. Axxam has target discovery programs in several major therapeutic areas including chronic pain, respiratory, osteoporosis, and cardiovascular.
About Ingenuity Systems®
Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotechnology companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. www.ingenuity.com.